PRACTICE AID Selected Clinical Trials in Gastric Cancer1
HER2+ Gastric Cancer
Monoclonal Antibody + PD-1 Inhibitor + CTX NCT03615326: KEYNOTE-811 Phase 3 Recruiting 732 participants Trastuzumab + CTX; pembrolizumab + trastuzumab + CTX; placebo + trastuzumab + CTX
Monoclonal Antibody Combinations Antiangiogenesis + CTX NCT04082364: MAHOGANY NCT03081143: RAMIRIS Phase 2/3 Recruiting 850 participants Recruiting 429 participants Margetuximab ± PD-1 inhibitor ± CTX ± dual checkpoint inhibitor Ramucirumab + FOLFIRI
ADC ADC Monoclonal Antibody + PD-L1 Inhibitor + CTX NCT03556345 NCT04014075: DESTINY-Gastric02 NCT03409848: INTEGA Active (127), not recruiting Recruiting 72 participants Recruiting 97 participants RC48-ADC Trastuzumab deruxtecan Nivolumab + trastuzumab + ipilimumab or FOLFOX Phase 2 ADC Bispecific Antibody + CTX NCT03329690: DESTINY-Gastric01 NCT03929666 Active (220), not recruiting Recruiting 115 participants Trastuzumab deruxtecan vs placebo ZW25 + CTX
Monoclonal Antibody + PD-L1 Inhibitor + CTX Bispecific Antibody + PD-1 Inhibitor Monoclonal Antibody + PD-1 Inhibitor NCT04379596: DESTINY-Gastric03 NCT04276493 NCT02689284 Phase 1b/2 Not yet recruiting (220) Recruiting 50 participants Active (95), not recruiting Trastuzumab deruxtecan monotherapy and ZW25 + tislelizumab + CTX Margetuximab + pembrolizumab combinations with CTX or durvalumab
ADC + PD-1 Inhibitor TKI + PD-L1 Inhibitor NCT04280341 NCT03539822: CAMILLA Phase 1 Not yet recruiting (50) Recruiting 30 participants RC48-ADC + JS001 Cabozantinib + durvalumab
Access the activity, “Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer,” at PeerView.com/GZH40 PRACTICE AID Selected Clinical Trials in Gastric Cancer1
Antiangiogenesis Combinations
Immunotherapy + Antiangiogenesis Immunotherapy + Antiangiogenesis CTX + Antiangiogenesis + CTX + CTX NCT03686488 Phase 2 NCT04069273: SEQUEL NCT03966118 Recruiting 25 participants Not yet recruiting (58) Recruiting 59 participants trifluridine/tipiracil + ramucirumab Pembrolizumab + ramucirumab + paclitaxel Avelumab + paclitaxel/ramucirumab
Antiangiogenesis + PARP + Immunotherapy PARP + Antiangiogenesis (RiME) NCT03008278 Phase 1/2 NCT03995017 Recruiting 49 participants Recruiting 61 participants Olaparib + ramucirumab Ramucirumab + rucaparib ± nivolumab
Immunotherapy + Antiangiogenesis Phase 1 NCT02572687 Active, not recruiting (114) Ramucirumab + durvalumab
Access the activity, “Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer,” at PeerView.com/GZH40 PRACTICE AID Selected Clinical Trials in Gastric Cancer1
Immunotherapy and Combinations
IImmunotherapy + CTX Immunotherapy + CTX Immunotherapy + CTX NCT03675737: NCT03221426: NCT03745170: ORIENT-16 Phase 3 KEYNOTE-859 KEYNOTE-585 Recruiting 650 participants Recruiting 1,542 participants Recruiting 1,000 participants Sintilimab + oxaliplatin + capecitabine Pembrolizumab + CTX Pembrolizumab + CTX
Immunotherapy + PARP Immunotherapy + PARP Immunotherapy + TKI NCT03579784 NCT04209686 NCT04164979 Recruiting 40 participants Not yet recruiting (36) Recruiting 20 participants Paclitaxel + olaparib then durvalumab + Paclitaxel + olaparib + pembrolizumab Cabozantinib + pembrolizumab olaparib + paclitaxel
Phase 1
Immunotherapy + DKK1 Neutralizing Antibody Immunotherapy + Monoclonal Antibody + Chemotherapy NCT04099641 NCT04363801: DisTinGuish Recruiting 80 participants Not yet recruiting (72) Bavituximab + pembrolizumab DKN-01 + tislelizumab ± CTX
Immunotherapy + PARP Immunotherapy Combinations PD-1 + CTLA-4 Inhibition Phase 1/2 NCT02734004: MEDIOLA NCT03281369 NCT04202601 Active, not recruiting (427) Recruiting 410 participants Recruiting 80 participants Durvalumab + olaparib Atezolizumab + various combinations Sintilimab + IBI310
Access the activity, “Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer,” at PeerView.com/GZH40 PRACTICE AID Selected Clinical Trials in Gastric Cancer1
Other Therapies and Strategies
PARP Inhibitor FGFR Inhibitor NCT03427814: PARALLEL 303 NCT03694522: FIGHT Active, not recruiting (540) Recruiting 548 participants BGB-290 vs placebo Bemarituzumab + CTX Phase 3 Claudin 18.2-Positive Claudin 18.2-Positive NCT03653507: GLOW NCT03504397: SPOTLIGHT Recruiting 500 participants Recruiting 550 participants Zolbetuximab + CTX Zolbetuximab + CTX
AKT Small Molecule Inhibitor Claudin 18.2-positive NCT01896531 NCT03505320: ILUSTRO Active (154), not recruiting Recruiting 112 participants Ipatasertib + CTX Cohort 1: Zolbetuximab; Cohort 2: Zolbetuximab + CTX; Phase 2 Cohort 3: Zolbetuximab + pembrolizumab FGFR Inhibitor NCT04189445 Not yet recruiting (115) Futibatinib (TAS-120)
CTX Platform Combo NCT03368963 Phase 1/2 Recruiting 64 participants trifluridine/tipiracil + nanoliposomal irinotecan
ADC: antibody–drug conjugates; CTLA-4: cytotoxic T-lymphocyte–associated protein 4; CTX: chemotherapy; PARP: poly ADP-ribose polymerase; PD-1: programmed cell death protein 1. 1. https://clinicaltrials.gov. Access the activity, “Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer,” at PeerView.com/GZH40